Clinical Analysis In 64 Lung Cancer Patients With Brain Metastases

Objective:This study was done to provide help for clinical treatment by analyz-ing the prognostic factors and the impact of multitreatment modalities over sur-vival in lung cancer patients with brain metastases.Methods:We reviewed the clinical data of 64 lung cancer patients with brain metastases in our hospital from the year of 2004 to 2009. The multivariate analysis was performed with Cox's proportion risk model. According to the treatment modalities, patients were divided into comprehensive treatment group and whole brain radiotherapy(WBRT) group, comprehensive treatment group were divided into whole brain radiotherapy(WBRT) plus chemotherapy group and WBRT/chemotherapy plus targeting therapy group. Survival analysis was compared with Kaplan-Meier method and log-rank test was used respectively. Statistical significance was defined as P<0.05.Results:The univariate analysis showed that patients'performance status and the absence or presence of extracranial metastases were related to survival period. The multivariate analysis indicated that patients'performance status and the absence or presence of extracranial metastases were closely related to their prognosis. The median survival time(MST) of multimodality treatment group and whole brain radiotherapy(WBRT) group was 16 and 6.9 months. The median survival time(MST) of whole brain radiotherapy(WBRT) plus chemotherapy group and WBRT/chemotherapy plus targeting therapy group was 11.6 months and 16.3 months.Conclusion:Performance status and the absence or presence of extracranial metas-tses are the independent prognostic factors in lung cancer with brain metastases. The patients with PS score 0-1 and absence of extracranial metastases have longer survival time and they would benefit from multi-treatment modalities. There maybe a relatively longer survival trend in the patients with multimodality treatment group,whole brain radiotherapy(WBRT) plus chemotherapy group and WBRT/chemotherapy plus targeting therapy group than those with simple whole brain radiotherapy(WBRT) group. In order to grain more survival benefit in targeting therapy, we should choose proper patients.